Please ensure Javascript is enabled for purposes of website accessibility

Why Are Participants in Novavax's COVID Vaccine Study Receiving 2 Extra Shots?

By Keith Speights and Brian Orelli, PhD - Apr 14, 2021 at 6:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There's a simple -- and good -- reason.

Like most of the other COVID-19 vaccines that have already won Emergency Use Authorization (EUA), Novavax's (NVAX 2.68%) vaccine requires two shots spread several weeks apart. But the biotech recently announced that participants in its late-stage clinical studies will have the option to receive two additional shots. In this Motley Fool Live video recorded on April 7, Motley Fool contributors Keith Speights and Brian Orelli talk about why Novavax is making this move.

Keith Speights: Novavax, the ticker there is NVAX, recently announced that it has initiated crossover arms with its late-stage studies that are going on in the United Kingdom, and in the U.S. and Mexico. Again, these are late-stage studies of its COVID-19 vaccine. Participants in these studies will be given the choice of receiving two extra shots in addition to the two shots they already received. Brian, what's the rationale behind this move?

Brian Orelli: It's a two-for-one deal. Novavax gets twice as much data for the same number of participants.

Of course, the cost isn't the same. They're only really saving money on the recruiting costs. The people participating presumably are getting twice as much money, and then they're having to pay the doctors twice as much. But they are getting more data, so they're crossing over patients in the placebo group, they're now going to get the vaccine, and people in the vaccine group are now going to get the placebo.

I was a little surprised that they were going to do the vaccine to the placebo crossover. I figured it would be a one-way open-label study where everybody who originally got the placebo will be told, "You got the placebo, and so now we're going to give you the vaccine."

But this should theoretically give them more data by also not telling the people who got the vaccine that they got the vaccine and then giving them the placebo. I'm curious how the company is handling the people who don't want to continue the study. Are they going to disclose to them which group they were in? Did they get the vaccine, or did they get the placebo.

Speights: This is a way, right, Brian, for Novavax to keep people in the study yet still be assured that they're going to get vaccinated?

Orelli: Yeah. Typically in almost every clinical trial, if you're in the placebo group, you're offered the drug, whatever it is, vaccine or whatever, after the end of the study. The chances you're going to get the placebo is because you know you'll eventually going to get this drug, and assuming it works, they'll give it to everybody.

Novavax gets extra data by then now studying in all the people who didn't get the placebo. They got a placebo originally, now they'll get more data on them getting the vaccine. Mostly I think they're looking at side effects here because, so now everybody in the clinical trial will have been vaccinated, they won't have a comparator to look at the actual rate of COVID-19 infections.

Speights: Now this will not impact Novavax's schedule or timeline for filing for Emergency Use Authorization.

Brian Orelli, PhD owns shares of Novavax. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$41.36 (2.68%) $1.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.